X4 Pharmaceuticals (XFOR) EPS (Basic) Growth (1y) (2018 - 2025)
X4 Pharmaceuticals (XFOR) EPS (Basic) Growth (1y) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | 29.25% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.41 Bn | 466.62 Bn | 1.35 Bn | 17,151.81% |
| 5 | Vertex Pharmaceuticals | 122.15 Bn | 114.90 Bn | 2.59 Bn | 61.34% |
| 6 | Regeneron Pharmaceuticals | 69.94 Bn | 61.18 Bn | 3.31 Bn | -7.74% |
| 7 | Belite Bio | 62.43 Bn | 62.43 Bn | - | - |
| 8 | Argenx Se | 55.85 Bn | 50.67 Bn | 1.41 Bn | 88.81% |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 1,201.33% |
| 10 | X4 Pharmaceuticals | 166.21 Mn | -50.84 Mn | 2.20 Mn | 90.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 90.49% |
| Sep 30, 2025 | 87.42% |
| Jun 30, 2025 | -125.55% |
| Mar 31, 2025 | 100.52% |
| Dec 31, 2024 | -84.13% |
| Sep 30, 2024 | -1,459.37% |
| Jun 30, 2024 | 237.24% |
| Mar 31, 2024 | -57.40% |
| Dec 31, 2023 | 76.52% |
| Sep 30, 2023 | 95.55% |
| Jun 30, 2023 | 44.84% |
| Mar 31, 2023 | 77.08% |
| Dec 31, 2022 | 67.15% |
| Sep 30, 2022 | 65.33% |
| Jun 30, 2022 | 19.14% |
| Mar 31, 2022 | 44.64% |
| Dec 31, 2021 | -52.18% |
| Sep 30, 2021 | 12.73% |
| Jun 30, 2021 | 2.08% |
| Mar 31, 2021 | -133.07% |